الفهرس 
Breast CancerOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
Breast cancer is the most prevalent malignancy according to estimates in Egyptian women. It is also a major contributor to cancer-related mortality, despite greater general awareness of the condition. The polymorphism in the FCG3A gene encoding for the Fc fragment of the IgG receptor could affect the efficacy of trastuzumab. The objective of this study was to investigate the association between FCGR3A-V158F gene polymorphism and response to trastuzumab in-HER2-positive breast cancer patients. Fifty breast cancer patients participated in this study, 23 responders (46%) and 27 non-responders (54%). All the patients were recruited from the Oncology Department at Ain Shams University Hospitals. Genetic polymorphisms of FCGR3A-V158F rs396991 were detected using real-time polymerase chain reaction (RT-PCR). No association was found between the FCGR3A-V158F genotype and the clinicopathological characteristics including age, family history, tumor side, lymph nodes, histopathological grade, and hormonal receptor status. A non-significant statistical difference was found regarding the genotypes and allelic distribution in responders as compared to non-responders, whereas patients carrying VV genotypes of FCGR3A-V158F were found to be associated with better response when compared with FF genotype. In conclusion, our findings indicate that patients carrying the VV genotype of FCGR3A-V158F are more likely to have a good response to trastuzumab in comparison to those with the FF genotype.